Ascendiant Capital reiterates Buy on Allarity Therapeutics; $11 target
Ascendiant Capital maintained a Buy rating on Allarity Therapeutics and kept a $11.00 price target, implying upside of 891.0% versus the Sep 15 close of $1.11.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.